US5917017A
(en)
*
|
1994-06-08 |
1999-06-29 |
President And Fellows Of Harvard College |
Diphtheria toxin vaccines bearing a mutated R domain
|
US6455673B1
(en)
*
|
1994-06-08 |
2002-09-24 |
President And Fellows Of Harvard College |
Multi-mutant diphtheria toxin vaccines
|
US5843462A
(en)
*
|
1995-11-30 |
1998-12-01 |
Regents Of The University Of Minnesota |
Diphtheria toxin epitopes
|
GB0108364D0
(en)
|
2001-04-03 |
2001-05-23 |
Glaxosmithkline Biolog Sa |
Vaccine composition
|
HU227613B1
(en)
*
|
2000-06-29 |
2011-09-28 |
Glaxosmithkline Biolog Sa |
Vaccine composition
|
EP1947116B1
(de)
*
|
2003-02-10 |
2017-06-21 |
2-BBB Medicines B.V. |
Differenziell exprimierte Nukleinsäuren der Blut-Hirnschranke bei einer Entzündung
|
KR101228204B1
(ko)
|
2003-02-10 |
2013-01-31 |
투-비비비 홀딩 비.브이. |
염증성 상태 하에 있는 뇌-혈관 장벽에서 차등 발현되는핵산
|
EP1667712B1
(de)
|
2003-10-02 |
2010-07-21 |
GlaxoSmithKline Biologicals S.A. |
B. pertussis antigene und ihre verwendung bei der vakzinierung
|
EP1687016A4
(de)
|
2003-11-25 |
2009-07-29 |
Anjin Corp |
Diphertie-toxin-variante
|
GB0505996D0
(en)
|
2005-03-23 |
2005-04-27 |
Glaxosmithkline Biolog Sa |
Fermentation process
|
US7179159B2
(en)
*
|
2005-05-02 |
2007-02-20 |
Applied Materials, Inc. |
Materials for chemical mechanical polishing
|
PE20110072A1
(es)
*
|
2005-06-27 |
2011-02-04 |
Glaxosmithkline Biolog Sa |
Composicion inmunogenica
|
GB0607088D0
(en)
|
2006-04-07 |
2006-05-17 |
Glaxosmithkline Biolog Sa |
Vaccine
|
NZ569168A
(en)
|
2005-12-22 |
2012-02-24 |
Glaxosmithkline Biolog Sa |
Streptococcus pneumoniae polysaccharide conjugate vaccine comprising 19F-DT conjugate
|
EP2066344B2
(de)
|
2006-09-07 |
2016-06-29 |
GlaxoSmithKline Biologicals S.A. |
Inaktiviertes Poliovirus Mischimpfstoff
|
UY31064A1
(es)
|
2007-05-02 |
2009-01-05 |
Glaxosmithkline Biolog Sa |
Vacuna
|
US8252897B2
(en)
*
|
2007-06-21 |
2012-08-28 |
Angelica Therapeutics, Inc. |
Modified toxins
|
KR101579947B1
(ko)
|
2007-06-26 |
2015-12-28 |
글락소스미스클라인 바이오로지칼즈 에스.에이. |
스트렙토코쿠스 뉴모니애 캡슐 다당류 컨쥬게이트를 포함하는 백신
|
EP2268297A4
(de)
*
|
2008-02-29 |
2011-11-16 |
Angelica Therapeutics Inc |
Modifizierte toxine
|
JP5722782B2
(ja)
*
|
2008-09-26 |
2015-05-27 |
ナノバイオ コーポレーション |
ナノエマルジョン治療用組成物及びその使用方法
|
US20120052088A1
(en)
|
2009-04-30 |
2012-03-01 |
Coley Pharmaceutical Group, Inc. |
Pneumococcal vaccine and uses thereof
|
WO2010132833A1
(en)
|
2009-05-14 |
2010-11-18 |
The Regents Of The University Of Michigan |
Streptococcus vaccine compositions and methods of using the same
|
WO2011027257A2
(en)
|
2009-09-03 |
2011-03-10 |
Pfizer Vaccines Llc |
Pcsk9 vaccine
|
GB0917647D0
(en)
|
2009-10-08 |
2009-11-25 |
Glaxosmithkline Biolog Sa |
Expression system
|
GB201003922D0
(en)
|
2010-03-09 |
2010-04-21 |
Glaxosmithkline Biolog Sa |
Conjugation process
|
SG10201407036YA
(en)
|
2010-11-05 |
2014-12-30 |
Transbio Ltd |
Markers of Endothelial Progenitor Cells and Uses Thereof
|
WO2012131504A1
(en)
|
2011-03-02 |
2012-10-04 |
Pfizer Inc. |
Pcsk9 vaccine
|
GB201103836D0
(en)
|
2011-03-07 |
2011-04-20 |
Glaxosmithkline Biolog Sa |
Conjugation process
|
GB201105981D0
(en)
|
2011-04-08 |
2011-05-18 |
Glaxosmithkline Biolog Sa |
Novel process
|
SA115360586B1
(ar)
|
2012-03-09 |
2017-04-12 |
فايزر انك |
تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها
|
FR2988393B1
(fr)
*
|
2012-03-20 |
2014-05-09 |
Commissariat Energie Atomique |
Inhibiteur de l'hb-egf derive du domaine r de la toxine diphterique pour le traitement des maladies associees a l'activation de la voie hb-egf/egfr
|
US9764006B2
(en)
|
2012-12-10 |
2017-09-19 |
The General Hospital Corporation |
Bivalent IL-2 fusion toxins
|
ES2597832T3
(es)
|
2013-03-08 |
2017-01-23 |
Janssen Vaccines & Prevention B.V. |
Vacuna acelular contra la tosferina
|
EP2964665B1
(de)
|
2013-03-08 |
2018-08-01 |
Pfizer Inc |
Immunogene fusionspolypeptide
|
CA2902905A1
(en)
|
2013-03-15 |
2014-09-25 |
Claude Geoffrey Davis |
Modified toxins
|
RU2662968C2
(ru)
|
2013-09-08 |
2018-07-31 |
Пфайзер Инк. |
Иммуногенная композиция против neisseria meningitidis (варианты)
|
WO2015095868A1
(en)
|
2013-12-20 |
2015-06-25 |
Wake Forest University Health Sciences |
Methods and compositions for increasing protective antibody levels induced by pneumococcal polysaccharide vaccines
|
BR122023022294A2
(pt)
|
2014-01-21 |
2023-12-12 |
Pfizer Inc. |
Uso de uma composição imunogênica que compreende um conjugado imunogênico compreendendo um polissacarídeo capsular isolado de streptococcus pneumoniae do sorotipo 15b
|
US9492559B2
(en)
|
2014-01-21 |
2016-11-15 |
Pfizer Inc. |
Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
|
US11160855B2
(en)
|
2014-01-21 |
2021-11-02 |
Pfizer Inc. |
Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
|
KR102099741B1
(ko)
|
2014-01-21 |
2020-04-10 |
화이자 인코포레이티드 |
스트렙토코쿠스 뉴모니아에 피막 폴리사카라이드 및 그의 접합체
|
JP2017505792A
(ja)
|
2014-02-14 |
2017-02-23 |
ファイザー・インク |
免疫原性糖タンパク質コンジュゲート
|
US10653764B2
(en)
|
2015-01-15 |
2020-05-19 |
Pfizer Inc. |
Immunogenic compositions for use in pneumococcal vaccines
|
CN108139375A
(zh)
|
2015-06-26 |
2018-06-08 |
贝斯以色列女执事医疗中心股份有限公司 |
靶向髓样衍生的抑制细胞中的四跨膜蛋白33(tspan33)的癌症疗法
|
SG10202005253TA
(en)
|
2015-07-21 |
2020-07-29 |
Pfizer |
Immunogenic compositions comprising conjugated capsular saccharide antigens, kits comprising the same and uses thereof
|
GB201518684D0
(en)
|
2015-10-21 |
2015-12-02 |
Glaxosmithkline Biolog Sa |
Vaccine
|
EP3377098A1
(de)
|
2015-11-20 |
2018-09-26 |
Pfizer Inc |
Immunogene zusammensetzungen zur verwendung in pneumokokkenimpfstoffen
|
NZ742663A
(en)
|
2015-12-04 |
2023-02-24 |
Dana Farber Cancer Inst Inc |
Vaccination with mica/b alpha 3 domain for the treatment of cancer
|
BR112019014833A2
(pt)
|
2017-01-20 |
2020-04-14 |
Pfizer |
composições imunogênicas para uso em vacinas pneumococais
|
SG11201906519RA
(en)
|
2017-01-31 |
2019-08-27 |
Pfizer |
Neisseria meningitidis compositions and methods thereof
|
KR102650073B1
(ko)
|
2017-01-31 |
2024-03-20 |
머크 샤프 앤드 돔 엘엘씨 |
스트렙토코커스 뉴모니아 혈청형 19f 유래의 협막 다당류 단백질 접합체의 제조 방법
|
WO2018156465A1
(en)
*
|
2017-02-24 |
2018-08-30 |
Merck Sharp & Dohme Corp. |
Polysaccharide-protein conjugates utilizing diphtheria toxin fragment b as a carrier
|
CA3066020A1
(en)
|
2017-06-16 |
2018-12-20 |
Glaxosmithkline Biologicals Sa |
Method of treatment
|
AU2018328037B2
(en)
|
2017-09-07 |
2024-03-07 |
Merck Sharp & Dohme Llc |
Pneumococcal polysaccharides and their use in immunogenic polysaccharide-carrier protein conjugates
|
JP7369123B2
(ja)
|
2017-12-06 |
2023-10-25 |
メルク・シャープ・アンド・ドーム・エルエルシー |
肺炎球菌多糖類-タンパク質コンジュゲートを含む組成物およびその使用方法
|
CN112673054A
(zh)
|
2018-07-19 |
2021-04-16 |
葛兰素史密丝克莱恩生物有限公司 |
用于制备干燥多糖的方法
|
US11260119B2
(en)
|
2018-08-24 |
2022-03-01 |
Pfizer Inc. |
Escherichia coli compositions and methods thereof
|
EP3893926A1
(de)
|
2018-12-12 |
2021-10-20 |
Pfizer Inc. |
Immunogene multiple hetero-antigen-polysaccharid-protein-konjugate und deren verwendung
|
JP2022513458A
(ja)
|
2018-12-12 |
2022-02-08 |
グラクソスミスクライン バイオロジカルズ ソシエテ アノニム |
O-結合型グリコシル化のための修飾キャリアタンパク質
|
MA54533A
(fr)
|
2018-12-19 |
2022-03-30 |
Merck Sharp & Dohme |
Compositions comprenant des conjugués polysaccharide-protéine de streptococcus pneumoniae et leurs méthodes d'utilisation
|
EP3923982A1
(de)
|
2019-02-11 |
2021-12-22 |
Pfizer Inc. |
Neisseria meningitidis-zusammensetzungen und verfahren dafür
|
US20220127368A1
(en)
|
2019-02-19 |
2022-04-28 |
The Regents Of The University Of Colorado, A Body Corporate |
Bispecific immunotoxins targeting human cd25+ccr4+ tumors and regulatory t-cells
|
JP7239509B6
(ja)
|
2019-02-22 |
2023-03-28 |
ファイザー・インク |
細菌多糖類を精製するための方法
|
US20220184199A1
(en)
|
2019-04-10 |
2022-06-16 |
Pfizer Inc. |
Immunogenic compositions comprising conjugated capsular saccharide antigens, kits comprising the same and uses thereof
|
WO2021021729A1
(en)
|
2019-07-31 |
2021-02-04 |
Sanofi Pasteur Inc. |
Multivalent pneumococcal polysaccharide-protein conjugate compositions and methods of using the same
|
US20220401544A1
(en)
|
2019-09-27 |
2022-12-22 |
Pfizer Inc. |
Neisseria meningitidis compositions and methods thereof
|
MX2022005252A
(es)
|
2019-11-01 |
2022-06-08 |
Pfizer |
Composiciones de escherichia coli y metodos de las mismas.
|
JP2023503086A
(ja)
|
2019-11-22 |
2023-01-26 |
グラクソスミスクライン バイオロジカルズ ソシエテ アノニム |
細菌サッカリド複合糖質ワクチンの用法及び用量
|
EP4107192A1
(de)
|
2020-02-21 |
2022-12-28 |
Pfizer Inc. |
Reinigung von sacchariden
|
AU2021223184A1
(en)
|
2020-02-23 |
2022-08-18 |
Pfizer Inc. |
Escherichia coli compositions and methods thereof
|
WO2022084852A1
(en)
|
2020-10-22 |
2022-04-28 |
Pfizer Inc. |
Methods for purifying bacterial polysaccharides
|
IL302362A
(en)
|
2020-10-27 |
2023-06-01 |
Pfizer |
ESCHERICHIA COLI preparations and their methods
|
CA3200602A1
(en)
|
2020-11-04 |
2022-05-12 |
Pfizer Inc. |
Immunogenic compositions for use in pneumococcal vaccines
|
US20220202923A1
(en)
|
2020-12-23 |
2022-06-30 |
Pfizer Inc. |
E. coli fimh mutants and uses thereof
|
TW202245835A
(zh)
|
2021-02-04 |
2022-12-01 |
美商默沙東有限責任公司 |
用於肺炎球菌結合物疫苗之奈米乳化液佐劑組合物
|
WO2022234405A1
(en)
|
2021-05-03 |
2022-11-10 |
Pfizer Inc. |
Vaccination against bacterial and betacoronavirus infections
|
WO2022234416A1
(en)
|
2021-05-03 |
2022-11-10 |
Pfizer Inc. |
Vaccination against pneumoccocal and covid-19 infections
|
BR112023023671A2
(pt)
|
2021-05-28 |
2024-02-06 |
Pfizer |
Composições imunogênicas compreendendo antígenos de sacarídeo capsular conjugados e usos dos mesmos
|
CA3221075A1
(en)
|
2021-05-28 |
2022-12-01 |
Pfizer Inc. |
Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
|
WO2023135515A1
(en)
|
2022-01-13 |
2023-07-20 |
Pfizer Inc. |
Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
|
WO2023161817A1
(en)
|
2022-02-25 |
2023-08-31 |
Pfizer Inc. |
Methods for incorporating azido groups in bacterial capsular polysaccharides
|
WO2024084397A1
(en)
|
2022-10-19 |
2024-04-25 |
Pfizer Inc. |
Vaccination against pneumoccocal and covid-19 infections
|
WO2024110827A1
(en)
|
2022-11-21 |
2024-05-30 |
Pfizer Inc. |
Methods for preparing conjugated capsular saccharide antigens and uses thereof
|
WO2024110839A2
(en)
|
2022-11-22 |
2024-05-30 |
Pfizer Inc. |
Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
|
WO2024116096A1
(en)
|
2022-12-01 |
2024-06-06 |
Pfizer Inc. |
Pneumococcal conjugate vaccine formulations
|